Blood levels of five proteins involved in the body’s inflammatory response may be used to diagnose myasthenia gravis (MG)…
Margarida Maia, PhD
Science Writer
Margarida Maia, PhD, is a science and medical writer with a background in biochemistry and biomedical sciences. She studied in Portugal and Belgium and has been working in science communication for several years. She has been writing at Bionews since 2021. Her work focuses on explaining new research and medical developments on rare diseases in a clear and accessible way.
Education
- PhD in Biomedical Sciences, VIB & KU Leuven, Belgium
- Degree in Biochemistry, University of Porto, Portugal
Certifications
- Google Project Management: Professional Certificate
Published Works
- Valdez, Y, Maia, M, Conway EM. CD248: Reviewing its role in health and disease. Curr Drug Targets. 2012;13:432–439.
- Maia, M et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011;11:162.
- Antunes, R, Brandão, C, Maia, M, Arosa, FA. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells. Immunol Cell Biol. 2011;89:111–121.
- Maia, M et al. CD248 and its cytoplasmic domain: A therapeutic target for arthritis. Arthritis Rheum. 2010;62:.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
The first patient has been enrolled in a myasthenia gravis (MG) registry to collect clinical information from real-world settings…
Fifteen college or trade school scholarships are now available for people with myasthenia gravis (MG) and their immediate family…
People who recover from myasthenia gravis (MG) after long-term treatment have higher numbers of certain subsets of monocytes —…
People with myasthenia gravis (MG) have higher levels of a protein called neurofilament light chain (NfL) in their blood,…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an experimental treatment that…
Treatment with Vyvgart (efgartigimod alfa-fcab) helped reduce the impact of generalized myasthenia gravis (gMG) on activities of daily…
Tapping into PD-1/PD-L1 immune checkpoint proteins — which serve as a kind of natural off switch for an overactive immune…
A case report from Germany showed that two women with severe, treatment-resistant myasthenia gravis (MG) responded well to blinatumomab,…
Azathioprine did not outperform standard treatment in helping adults with myasthenia gravis (MG) live longer, and while older age…